- Naltrexone plus combined behavioural interventions at F3 reduced liver-related mortality and cirrhosis progression while lowering lifetime costs and increasing QALYs.
- The treatment strategy dominated baseline care and remained cost-effective across sensitivity analyses, even with relapse rates up to 100% and minimal adherence.
- Findings held when initiated at F1 and F2 and when including societal and alcohol use disorder costs, supporting early screening and treatment implementation.
JAMA Netw Open. 2026 Nov 2;9(11):e2644980. doi: 10.1001/jamanetworkopen.2026.44980.
ABSTRACT
IMPORTANCE: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and liver transplant. Combined behavioral interventions (CBI) and medications for alcohol use disorder (MAUD) are underutilized. Thus, it is critical to identify optimal therapeutic and cost-effective windows for CBI and MAUD in patients with ALD at earlier fibrosis stages.
OBJECTIVE: To evaluate the cost-effectiveness of naltrexone and CBI in preventing cirrhosis in patients with ALD compared with no treatment.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used a Markov state-transition model simulating lifetime disease progression and health care costs associated with ALD. The simulated patient cohort began at 45 years of age with active AUD and stage 3 fibrosis (F3) and could experience progression to compensated or decompensated cirrhosis.
EXPOSURE: All patients were assumed to complete a 16-week course of naltrexone along with 52 weeks of CBI.
MAIN OUTCOMES AND MEASURES: Primary outcomes included total health care cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Secondary outcomes included liver-related mortality and progression to compensated and decompensated cirrhosis. Scenario and sensitivity analyses were performed to determine outcomes at earlier stages and with varied cost and model parameters.
RESULTS: Without intervention, 61% of the cohort died from liver-related causes, 88% developed compensated cirrhosis, and 66% of those experienced progression to decompensated cirrhosis, with a lifetime cost of $79 799 per person. With treatment initiated at F3, liver-related mortality was reduced to 58%, lifetime compensated cirrhosis to 87%, and lifetime progression to decompensated cirrhosis to 62%, with a lifetime cost of $78 673. The treatment strategy dominated because the lifetime costs were lower and more QALYs were gained when compared with untreated natural history. Treatment was preferred in sensitivity analyses at relapse rates to 100% and adherence greater than 0%, in scenario analyses when treatment was initiated at stages F2 and F1, and for the models including societal and AUD costs.
CONCLUSIONS AND RELEVANCE: In this economic evaluation of AUD treatment for patients with ALD, treating patients with ALD with naltrexone and CBI at F3 saved cost and was more effective than no treatment, reducing progression to compensated and decompensated cirrhosis. The results remained true at stages F1 and F2 fibrosis and when considering the societal costs and the costs of AUD. Future studies should include prospective evaluations of screening strategies combined with early treatment, as many patients are diagnosed at advanced stages of ALD.
PMID:43050187 | DOI:10.1001/jamanetworkopen.2026.44980
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

